Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Metrics to compare | RNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −4.3x | −0.4x | |
PEG Ratio | - | −0.16 | 0.00 | |
Price/Book | −3.4x | 7.2x | 2.6x | |
Price / LTM Sales | 11.5x | 10.7x | 3.2x | |
Upside (Analyst Target) | 83.0% | 86.5% | 46.7% | |
Fair Value Upside | Unlock | 5.8% | 7.6% | Unlock |